SCOP Search:   
        by sunid, keyword
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  
(use 'Shift Left-Click' to collapse/expand all levels downwards; use 'Control Left-Click' to collapse/expand all levels upwards)
 
(-)
Class: Alpha and beta proteins (a+b) (23004)
(-)
Fold: Protein kinase-like (PK-like) (2589)
(-)
Superfamily: Protein kinase-like (PK-like) (2589)
(-)
Family: Protein kinases, catalytic subunit (1977)
(-)
Protein domain: Cyclin-dependent PK, CDK2 (340)
(-)
Human (Homo sapiens) [TaxId: 9606] (336)
1AQ1A:HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
1B38A:HUMAN CYCLIN-DEPENDENT KINASE 2
1B39A:HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
1BUHA:CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
1CKPA:HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
1DI8A:THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE
1DM2A:HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
1E1VA:HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
1E1XA:HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
1E9HA:; C:THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
1F5QA:; C:CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
1FINA:; C:CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
1FQ1B:CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
1FVTA:THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
1FVVA:; C:THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
1G5SA:CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
1GIHA:HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1GIIA:HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1GIJA:HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1GY3A:; C:PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE
1GZ8A:HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3'-METHYL-2'-OXO)BUTOXYPURINE
1H00A:CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1H01A:CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1H07A:CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1H08A:CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1H0VA:HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5'-YL]METHOXYPURINE
1H0WA:HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
1H1PA:; C:STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
1H1QA:; C:STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
1H1RA:; C:STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
1H1SA:; C:STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
1H24A:; C:CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
1H25A:; C:CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
1H26A:; C:CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
1H27A:; C:CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
1H28A:; C:CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
1HCKA:HUMAN CYCLIN-DEPENDENT KINASE 2
1HCLA:HUMAN CYCLIN-DEPENDENT KINASE 2
1JSTA:; C:PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
1JSUA:P27(KIP1)/CYCLIN A/CDK2 COMPLEX
1JSVA:THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
1JVPP:CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) IN COMPLEX WITH PKF049-365
1KE5A:CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
1KE6A:CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
1KE7A:CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE
1KE8A:CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE
1KE9A:CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE
1OGUA:; C:STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
1OI9A:; C:STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1OIQA:IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1OIRA:IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1OITA:IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1OIUA:; C:STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1OIYA:; C:STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1OKVA:; C:CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
1OKWA:; C:CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
1OL1A:; C:CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
1OL2A:; C:CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
1P2AA:THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
1P5EA:; C:THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE (TBS)
1PF8A:CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
1PKDA:; C:THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A
1PW2A:APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
1PXIA:HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(2,5-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2-YLAMINE
1PXJA:HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
1PXKA:HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'-HYDROXYIMINOFORMAMIDE
1PXLA:HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL-PHENYL)-AMINE
1PXMA:HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL
1PXNA:HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL
1PXOA:HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO-PHENYL)-AMINE
1PXPA:HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE
1PYEA:CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
1QMZA:; C:PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
1R78A:CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
1URCA:; C:CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
1URWA:CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B]PYRIDAZINE
1V1KA:CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1VYWA:; C:STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
1VYZA:STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
1W0XC:CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
1W8CA:CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H-PURIN-2-YLAMINE AND MONOMERIC CDK2
1W98A:THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
1WCCA:SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
1Y8YA:CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1, 5-A]PYRIMIDINE INHIBITOR
1Y91A:CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1, 5-A]PYRIMIDINE INHIBITOR
1YKRA:CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
2A0CX:HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II, A NOVEL 2,6,9-TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
2A4LA:HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
2B52A:HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH-042562
2B53A:HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN-234325
2B54A:HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN-232305
2B55A:HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
2BHEA:HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
2BHHA:HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
2BTRA:STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
2BTSA:STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
2C5NA:; C:DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2C5OA:; C:DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2C5VA:; C:DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2C5XA:; C:DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2C5YA:DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2C68A:CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2C69A:CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2C6IA:CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2C6KA:CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2C6LA:CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2C6MA:CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2C6OA:CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2C6TA:; C:CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2CCHA:; C:THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE
2CCIA:; C:CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
2CJMA:; C:MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
2CLXA:4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY, CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR EFFECTS
2DS1A:HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
2DUVA:STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
2EXMA:HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
2FVDA:CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
2G9XA:; C:STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
2I40A:; C:CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
2IW6A:1-295; C:STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2IW8A:1-297STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
2IW9A:; C:STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2J9MA:CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
2JGZA:CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
2R3FA:CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2R3GA:CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2R3HA:CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2R3IA:CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2R3JA:CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2R3KA:CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2R3LA:CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2R3MA:CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2R3NA:CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2R3OA:CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2R3PA:CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2R3QA:CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2R3RA:CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2R64A:CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
2UUEA:; C:REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2UZBA:; C:CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZDA:; C:CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZEA:; C:CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZLA:; C:CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZNA:CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZOA:CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2V0DA:CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2V22A:; C:REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2VTAA:IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2VTHA:IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
2VTIA:IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2VTJA:IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2VTLA:IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2VTMA:IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2VTNA:IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2VTOA:IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2VTPA:IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2VTQA:IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2VTRA:IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2VTSA:IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2VTTA:IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2VU3A:IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2VV9A:CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
2W05A:STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, COMPOUND 5B
2W06A:STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, COMPOUND 5C
2W17A:CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE, COMPOUND (S)-8B
2W1HA:FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283), A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
2WEVA:; C:TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2WFYA:; C:TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2WHBA:; C:TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2WMAA:; C:STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2WMBA:; C:STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2X1NA:; C:TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2XMYA:DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
2XNBA:DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
3BHTA:; C:STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
3BHUA:; C:STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
3BHVA:; C:STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
3DDPA:; C:STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
3DDQA:; C:STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
3DOGA:; C:STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
3EIDA:; C:CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
3EZRA:CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
3EZVA:CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
3F5XA:; C:CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
3FZ1A:CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
3IG7A:NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
3IGGA:NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
3LE6A:THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
3LFNA:CRYSTAL STRUCTURE OF CDK2 WITH SAR57, AN AMINOINDAZOLE TYPE INHIBITOR
3LFQA:CRYSTAL STRUCTURE OF CDK2 WITH SAR60, AN AMINOINDAZOLE TYPE INHIBITOR
3LFSA:CRYSTAL STRUCTURE OF CDK2 WITH SAR37, AN AMINOINDAZOLE TYPE INHIBITOR
3MY5A:; C:CDK2/CYCLINA IN COMPLEX WITH DRB
3NS9A:CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
3PJ8A:STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[4,3-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
3PXFA:CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
3PXQA:CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
3PXRA:APO CDK2 CRYSTALLIZED FROM JEFFAMINE
3PXYA:CDK2 IN COMPLEX WITH INHIBITOR JWS648
3PXZA:CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
3PY0A:CDK2 IN COMPLEX WITH INHIBITOR SU9516
3PY1A:CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
3QHRA:; C:STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
3QHWA:; C:STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
3QL8A:CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
3QQFA:CDK2 IN COMPLEX WITH INHIBITOR L1
3QQGA:CDK2 IN COMPLEX WITH INHIBITOR L2-5
3QQHA:CDK2 IN COMPLEX WITH INHIBITOR L2-2
3QQJA:CDK2 IN COMPLEX WITH INHIBITOR L2
3QQKA:CDK2 IN COMPLEX WITH INHIBITOR L4
3QQLA:CDK2 IN COMPLEX WITH INHIBITOR L3
3QRTA:CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
3QRUA:CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
3QTQA:CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
3QTRA:CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
3QTSA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
3QTUA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
3QTWA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
3QTXA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
3QTZA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
3QU0A:CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
3QWJA:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
3QWKA:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
3QX2A:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
3QX4A:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
3QXOA:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
3QXPA:CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
3QZFA:CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
3QZGA:CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
3QZHA:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
3QZIA:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
3R1QA:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
3R1SA:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
3R1YA:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
3R28A:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
3R6XA:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
3R71A:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
3R73A:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
3R7EA:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
3R7IA:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
3R7UA:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
3R7VA:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
3R7YA:CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
3R83A:CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
3R8LA:CDK2 IN COMPLEX WITH INHIBITOR L3-4
3R8MA:CDK2 IN COMPLEX WITH INHIBITOR L3-3
3R8PA:CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
3R8UA:CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
3R8VA:CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
3R8ZA:CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
3R9DA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
3R9HA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
3R9NA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
3R9OA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
3RAHA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
3RAIA:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
3RAKA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
3RALA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
3RJCA:CDK2 IN COMPLEX WITH INHIBITOR L4-12
3RK5A:CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
3RK7A:CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
3RK9A:CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
3RKBA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
3RM6A:CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
3RM7A:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
3RMFA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
3RNIA:CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
3ROYA:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
3RPOA:CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
3RPRA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
3RPVA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
3RPYA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
3RZBA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
3S00A:CDK2 IN COMPLEX WITH INHIBITOR L4-14
3S0OA:CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
3S1HA:CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
3S2PA:CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
3SQQA:CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
3SW4A:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
3SW7A:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
3TI1A:CDK2 IN COMPLEX WITH SUNITINIB
3TIYA:CDK2 IN COMPLEX WITH NSC 35676
3TIZA:CDK2 IN COMPLEX WITH NSC 111848
3TNWA:; C:STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
3ULIA:HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
3UNJA:CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
3UNKA:CDK2 IN COMPLEX WITH INHIBITOR YL5-083
3WBLA:CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
4ACMA:CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
4BCKA:; C:STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR
4BCMA:; C:STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR
4BCNA:; C:STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR
4BCOA:; C:STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR
4BCPA:; C:STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR
4BCQA:; C:STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR
4BGHA:CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
4CFNA:; C:STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
4CFWA:; C:STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
4EK3A:CRYSTAL STRUCTURE OF APO CDK2
4EK4A:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4EK5A:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4EK6A:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4EK8A:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4EOIA:; C:THR 160 PHOSPHORYLATED CDK2 K89D, Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
4EOJA:; C:THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
4EOKA:; C:THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
4EOLA:; C:THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
4EOMA:; C:THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
4EONA:; C:THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
4EOOA:; C:THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
4EOPA:; C:THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
4EOQA:; C:THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
4EORA:; C:THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
4EOSA:; C:THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
4ERWA:CDK2 IN COMPLEX WITH STAUROSPORINE
4EZ3A:CDK2 IN COMPLEX WITH NSC 134199
4EZ7A:CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONIC ACID
4FKGA:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4FKIA:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4FKJA:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4FKLA:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4FKOA:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4FKPA:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4FKQA:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4FKRA:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4FKSA:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4FKTA:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4FKUA:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4FKVA:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4FKWA:CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4FX3A:; C:CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
4GCJA:CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
4I3ZA:; C:STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
4II5A:; C:STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
4KD1A:CDK2 IN COMPLEX WITH DINACICLIB
4LYNA:CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-1,3-OXAZOL-2-YL)METHYL)SULFANYL)-1,3-THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
4NJ3A:MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE-BASED INHIBITOR
(-)
Malaria parasite (Plasmodium falciparum) [TaxId: 5833] (4)
1OB3A:; B:STRUCTURE OF P. FALCIPARUM PFPK5
1V0BA:; B:CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
1V0OA:; B:STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
1V0PA:; B:STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX